A combination of sorafenib and nilotinib reduces the growth of castrate-resistant prostate cancer
Monica Archibald,1 Tara Pritchard,1 Hayley Nehoff,1 Rhonda J Rosengren,1 Khaled Greish,1,2 Sebastien Taurin1 1Department of Pharmacology and Toxicology, University of Otago, Dunedin, New Zealand; 2Aljawhara Centre for Molecular Medicine, Arabian Gulf University, Manama, Kingdom of Bahrain Abstract...
Guardado en:
Autores principales: | Archibald M, Pritchard T, Nehoff H, Rosengren RJ, Greish K, Taurin S |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://doaj.org/article/59e61614d14143069f88a7a245383ea5 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Update on the management of Philadelphia chromosome positive chronic myelogenous leukemia: role of nilotinib
por: Emole J, et al.
Publicado: (2016) -
The effect of imatinib and nilotinib on blood calcium and blood potassium levels in chronic myeloid leukemia patient: a literature review
por: Muhammad Darwin Prenggono, et al.
Publicado: (2021) -
Metastatic castration-resistant prostate cancer in very elderly patients: challenges and solutions
por: Caffo O, et al.
Publicado: (2016) -
Cabazitaxel in the treatment of metastatic castration-resistant prostate cancer
por: Nikolai A. Ognerubov
Publicado: (2021) -
Targeting Inflammatory Signaling in Prostate Cancer Castration Resistance
por: Shangwei Zhong, et al.
Publicado: (2021)